monotherapy - 搜索视频

Daraxonrasib Monotherapy as First-Line (1L) Treatment for Patients With Metastatic Pancreatic Adenocarcinoma (mPDAC) | OncLive

Daraxonrasib Monotherapy as First-Line (1L) Treatment for Patients With Metastatic Pancreatic Adenocarcinoma (mPDAC) | OncLive

Dr. Sequist on Pembrolizumab Monotherapy in Nonsquamous NSCLC | OncLive

Dr. Sequist on Pembrolizumab Monotherapy in Nonsquamous NSCLC | OncLive

2019年8月8日

New Nonstatin Cholesterol Lowering Drugs: How to Use Them

New Nonstatin Cholesterol Lowering Drugs: How to Use Them

2022年9月27日

Options for Treatment of Advanced RCC After Progression With TKI Monotherapy

Options for Treatment of Advanced RCC After Progression With TKI Monotherapy

PsA and Obesity Management: Ixekizumab Plus Tirzepatide vs Monotherapy (TOGETHER Study)

PsA and Obesity Management: Ixekizumab Plus Tirzepatide vs Monotherapy (TOGETHER Study)

Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA | OncLive

Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA | OncLive

2024年1月12日

Combination Therapy vs Monotherapy in RA

Combination Therapy vs Monotherapy in RA

2022年6月22日

Video: Cemdisiran Monotherapy in Myasthenia Gravis—AAN 2026 Expert Insights

neurologyadvisor.com

Tecvayli monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

marketscreener.com

Evaluating the Case Against Combining Immune Checkpoint Inhibitors with BCG in Non-Muscle-Invasive Bladder Cancer - Félix Guerrero-Ramos

A Phase 1 Clinical Trial Evaluating Monotherapy With Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF‑Altered Solid Tumors and NRAS-Mutant Melanoma | OncLive

2023年4月27日

Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML

Dr Smith on the Role of Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer | OncLive

Real-World Treatment Patterns and Clinical Outcomes in Radioiodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) Patients Treated with Lenvatinib Monotherapy | OncLive

2022年11月30日

WCLC 2025 Insights: First-Line Osimertinib + Chemo vs. Osimertinib Monotherapy in EGFRm Advanced NSCLC - FLAURA2 Final Overall Survival

Cemiplimab Monotherapy for First Line Advanced NSCLC Patients With PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung | OncLive

2024年11月27日

Hutchmed Begins Phase 1 Study of HMPL-A251 Monotherapy to Treat Patients With Solid Tumors

marketscreener.com

Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial

2024年2月15日

proactiveinvestors.com

ASCO® GU 2024 Insights: "EMBARK Trial - Outcomes of Men With High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment"

2024年2月20日

Lifileucel TIL Cell Monotherapy in Patients With Advanced Melanoma After Progression on Immune Checkpoint Inhibitors and Targeted Therapy: Pooled Analysis of Consecutive Cohorts (C-144-01 Study) | OncLive

2023年2月20日

Protocol AC: Step Therapy in DME - Eyetube

2023年4月17日

Imugene’s Phase 1 onCARlytics clinical trial doses first patient in intravenous monotherapy arm

2024年2月14日

proactiveinvestors.com

Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

2024年12月19日

Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC | OncLive

2024年7月16日

Adagrasib Yields Durable Benefit for Patients With KRAS G12C–Mutant NSCLC | OncLive

2023年9月10日

Comparison of Nationally Representative Samples of Rasburicase vs Allopurinol Post-Hyperuricemia Monotherapy in Hematological Malignancies: Significant Reduction in Tumor Lysis Syndrome Mortality with Rasburicase | OncLive

2022年10月14日

EV P Combination Strategy Changing Bladder Cancer Treatment Landscape | AJMC

2022年11月4日

Dr Kittai on an Indirect Comparison of Acalabrutinib Plus Obinutuzumab vs Zanubrutinib in CLL/SLL | OncLive

2023年10月11日

Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)

2023年11月16日

businesswire.com

Dr Kim Discusses HOST-EXAM Trial Results ACC26 | JACC Journals posted on the topic | LinkedIn

已浏览 1.8万次3 周前

展开